Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|13|4|483-494

ISSN： 1389-4501

Source： Current Drug Targets, Vol.13, Iss.4, 2012-04, pp. : 483-494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-07 ,pp. : 1692-1706

Bentham Science Publishers

Access to resources Recommend Favorite

Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

By Martinez Ana   Castro Ana  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite

Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-01 ,pp. : 777-785

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

By Jönsson L.  

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats

By Kosasa T.   Kuriya Y.   Matsui K.   Yamanishi Y.  

European Journal of Pharmacology, Vol. 389, Iss. 2, 2000-02 ,pp. : 173-179

Elsevier

Access to resources Recommend Favorite